The enhanced levels of AST and ALT were lowered after the treatment significantly and dose-dependently with M1 inferring its ability to reduce hepatocarcinogenic features in HCC-bearing rats, similar to 5-FU. This evidence concerns the gene GPT and hepatocellular carcinoma.